According to the tumor growth curves shown in Figure 6C, RGS significantly inhibited tumor growth compared to PBS treatment; moreover, tumor growth was slower in the RGS-treated group than in the 5-FU + oxaliplatin + bevacizumab and 5-FU + irinotecan + bevacizumab groups. The gene discussed is PITX2; the disease is neoplasm.